EUCTR2007-004225-26-IT
进行中（未招募）
不适用
A multicenter, randomised, double-blind, double-dummy, phase III study of the safety and efficacy of Ritonavir-boosted Elvitegravir (EVG/r) versus Raltegravir (RAL) each administered with a background regimen in HIV-1 infected, antiretroviral treatment-experienced adults. - ND
Gilead Sciences Incorporated0 个研究点目标入组 700 人2008年7月21日
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- HIV-1 infection
- 发起方
- Gilead Sciences Incorporated
- 入组人数
- 700
- 状态
- 进行中（未招募）
- 最后更新
- 10年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •. Plasma HIV\-1 RNA levels \> or \= 1000 copies/ml at screening . Documented viral resistance or at least six months experienced prior to screening with two or more different classes of antiretroviral agents. . Stable current antiretroviral regimen for at least 30 days prior to screening . No prior treatment with any HIV\-1 integrase inhibitor.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
排除标准
- •. A new AIDS\-defining condition diagnosed within the 30 days prior to screening . Prior treatment with any HIV\-1 integrase inhibitor . Subjects experiencing ascites or encephalopathy . Females who are breastfeeding . Positive serum pregnancy at any time during the study
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioEUCTR2015-002168-17-NLBayer HealthCare AG5,890
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioSubjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or bothMedDRA version: 18.1Level: LLTClassification code 10076410Term: Chronic kidney disease stage 3System Organ Class: 100000004857MedDRA version: 18.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861MedDRA version: 18.1Level: LLTClassification code 10066498Term: Cardiac failure chronic aggravatedSystem Organ Class: 100000004849MedDRA version: 18.1Level: LLTClassification code 10076408Term: Chronic kidney disease stage 1System Organ Class: 100000004857MedDRA version: 18.1Level: LLTClassification code 10076409Term: Chronic kidney disease stage 2System Organ Class: 100000004857Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2015-002168-17-ESBayer HealthCare AG5,890
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioEUCTR2015-002168-17-HUBayer HealthCare AG5,890
进行中（未招募）
不适用
A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to sitagliptin and placebo in patients with type 2 diabetesmellitus inadequately controlled with metformin. - EMERGE 4Type 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2008-001854-42-DEF.Hoffmann-La Roche Ltd630
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioEUCTR2015-002168-17-FIBayer HealthCare AG5,890